RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors

Trial Profile

RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms RIFTOS MKI
  • Sponsors Bayer
  • Most Recent Events

    • 07 Jul 2017 Planned End Date changed from 1 Jul 2020 to 31 Jul 2020.
    • 06 Jun 2017 Interim results (n=274) assessing use of multikinase inhibitors presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 15 May 2017 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top